So far, adjuvant EGFR-TKI of osimertinib has been considered to be recommended for resected NSCLC as an adjuvant treatment option by guidelines, but adjuvant cisplatin-based chemotherapy is still the preferred recommendation [29]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.